Business Wire

Blue Cloud Ventures Expands to Europe With New Office in Berlin


Blue Cloud Management LLC (“Blue Cloud Ventures” or “BCV”), a leading venture capital firm headquartered in New York City, is proud to announce the opening of its European office in Berlin. Blue Cloud Ventures is a growth-stage VC focused on B2B SaaS companies globally. BCV has invested in 43 companies to date, including investments in European companies such as Cognism, Templafy, and most recently, LMS365.

This press release features multimedia. View the full release here:

To view this piece of content from, please give your consent at the top of this page.

Blue Cloud Ventures Team (Photo: Business Wire)

With the European tech scene experiencing rapid growth over the past few years, BCV is keen to be part of this emerging ecosystem and partner with founders and investors in the region.

The office will be headed by Victor Yaw, who has been involved in BCV's investments such as Paradox, Trulioo, and Go1, as well as Cognism, Templafy, and LMS365 in Europe.

“We’re thrilled that Victor will be leading our efforts to expand our global footprint; we have been deepening our presence across various regions since raising our fourth fund and see a surge in high-quality B2B SaaS companies being built in Europe,” said Rami Rahal, co-founder and Managing Partner of BCV.

Leveraging its deep U.S. roots, its LP network of 100+ technologists and entrepreneurs globally, and connections across equity and debt funds and service providers, BCV aims to bring a unique set of value-add to European B2B SaaS companies. Through its European presence, BCV will also work closely with its existing portfolio companies in the region, supporting them on their growth journey.

“Since our founding, we have remained focused on being the best partners to our entrepreneurs and their teams,” said Mir Arif, co-founder and Managing Partner of BCV. “We are proud of our readiness to roll up our sleeves and add value, whether by acting as a sounding board to founders, or by assisting with strategy, M&A, recruiting, or customer introductions.”

Berlin was a natural choice for BCV's expansion into Europe, given its status as a tech hub for the region, its location at the heart of the Europe, and its connectivity with other major European cities. The city has a supportive ecosystem for early-stage startups and is quickly emerging as a major hub for companies looking to scale to multi-billion outcomes.

“We are at a key inflection point for B2B SaaS in Europe," said Victor Yaw. "We’ve seen the emergence of a next generation of company builders that have developed the expertise to truly scale to become category-defining platforms. We are excited about our existing investments in the region and believe that this is just the tip of the iceberg."

About Blue Cloud Ventures

Blue Cloud Ventures (BCV) is a software-focused growth stage venture capital fund firm headquartered in New York City. The fund targets investments in leading business applications, infrastructure and open-source software companies. Some of BCV’s past and present portfolio companies include Arctic Wolf Networks, Clari, Cloudbees, Druva, Go1, Iterable, NGINX, Templafy, Pax8 and Wrike. For more information on BCV and our portfolio companies, please visit

Disclaimer - Nothing presented within this article is intended to constitute investment advice, and under no circumstances should any information provided herein be used or considered as an offer to sell or a solicitation of an offer to buy an interest in any investment fund managed by Blue Cloud Management LLC (“Blue Cloud Ventures”). Blue Cloud Ventures does not provide investment advice and is not registered in Germany. Information provided reflects Blue Cloud Ventures’ views as of a time, whereby such views are subject to change at any point and Blue Cloud Ventures shall not be obligated to provide notice of any change. Nothing contained in this article may be relied upon as a guarantee or assurance as to the future success of any particular company. Companies mentioned in this article are a representative sample of portfolio companies in which Blue Cloud Ventures has invested in which the author believes such companies fit the objective criteria stated in commentary, which do not reflect all investments made by Blue Cloud Ventures. Blue Cloud Ventures does not solicit or make its services available to the public and none of the funds are currently open to new investors. While Blue Cloud Ventures has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability, or completeness of third-party information presented herein, which is subject to change. Past performance is not indicative of future results.

To view this piece of content from, please give your consent at the top of this page.

Contact information

Victor Yaw:
Julie Hoagland Sorensen:

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ilsong Educational Foundation Chairman Dai-Won Yoon Wins Linnaeus Medal as the First in Asia2.6.2023 12:00:00 EEST | Press release

On May 30, Chairman Dai-Won Yoon of Ilsong Educational Foundation received the Linnaeus Medal from Uppsala University at Hallym University. This makes him the first person from Asia to receive the award. Ilsong Educational Foundation operates Hallym University and Hallym University Medical Center. This press release features multimedia. View the full release here: Chairman Dai-Won Yoon (left) of Ilsong Educational Foundation received Linnaeus Medal as the 1st in Asia (Photo: Hallym University) Chairman Yoon is the honoree of 2020. The award ceremony, which had been postponed due to COVID-19, was held this year with a delegation led by Vice Chancellor Anders Hagfeldt of Uppsala University visiting Korea. The Linnaeus Medal to commemorate Carl Linnaeus, a Swedish botanist, is awarded annually by Uppsala University to a person who has made a significant contribution to the field of science. Chairman Yoon was honored for his work in

10th Annual World Patient Safety, Science & Technology Summit Begins2.6.2023 09:15:00 EEST | Press release

Day one of the 10th Annual World Patient Safety, Science & Technology Summit presented by the Patient Safety Movement Foundation (PSMF) saw global leaders across the world of patient safety call for an increased urgency in addressing the issue of preventable harm within healthcare. This press release features multimedia. View the full release here: Joe Kiani, founder of the Patient Safety Movement Foundation, speaks at the 10th Annual World Patient Safety, Science & Technology Summit in Newport Beach, California. (Photo: Business Wire) Celebrating the PSMF’s 10th anniversary, Dr. Michael Ramsay, chief executive officer of the PSMF, reflected on the role that the increasing availability of hospital data on medical errors could play in reducing harm. “I’m very optimistic that we’re really going to see a difference in healthcare,” he said. “Technology is changing. We’re now getting real data. We know what the outcomes are in hospit

Autel Energy Holds Partner Summit in Amsterdam, Mapping Out Europe Strategy2.6.2023 09:00:00 EEST | Press release

Autel Energy, a leading provider of EV charging products and services, successfully hosted the Autel Partner Summit at Muziekgebouw in Amsterdam from May 31 to June 1, 2023. The event not only showcased Autel’s visionary Europe strategy for the next two years but also provided partners opportunities to gain insights into the company's vision, and learn about Autel’s new products. This press release features multimedia. View the full release here: A quick afternoon bite with the Autel partners. (Photo: Business Wire) The Partner Summit helped Autel Energy to strengthen its partnerships in Europe and highlighted its collaborations with key clients. Notable partners in attendance included Maxicharger AC clients such as Sevadis and Deta, as well as Maxicharger DC clients such as Floading, Gasgas, and eWays. The company also partnered with CPO clients like Fastway and Powerdo, as well as energy companies like Enefit. The Summit was d

PL BioScience and Macopharma enter into a Patent License and Assignment Agreement regarding Human Platelet Lysate (HPL) cell culture supplements.2.6.2023 08:22:00 EEST | Press release

PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced a Patent License and Assignment Agreement with the French company Macopharma S.A.S. As a result of the Agreement, PL BioScience will hereby accept a worldwide license under the patents filed by Macopharma, with a right to sublicense (through multiple tiers), for the duration of the license period. In addition to the Patent License and Assignment Agreement, Macopharma will introduce PL BioScience to their current HPL customers, and thanks to a comprehensive comparative evaluation showing equivalence of HPL products from PL BioScience, Macopharma HPL customers will have the opportunity to transfer their future orders to PL BioScience with minimal disruption. About PL BioScience: Located in Aachen in Germany, PL BioScience GmbH is a life science company specializing in the production and development of Human Platelet Lysate (HP

AOP Health: Completed Study Strengthens Clinical Development Program for ropeginterferon alpha 2b (Besremi®) in polycythaemia vera2.6.2023 05:00:00 EEST | Press release

With the publication of the final results from the LOW-PV study in the New England Journal of Medicine Evidence conducted by Fondazione per la Ricerca dell'Ospedale di Bergamo (FROM) under the leadership of Professor Tiziano Barbui, AOP Health announces an important advancement reinforcing its clinical development program for ropeginterferon alpha-2b (BESREMi®) in polycythaemia vera (PV), a rare blood cancer. The academic LOW-PV study supported and funded by AOP Health and public organizations in Italy complements a series of trials performed by AOP Health over more than 10 years to achieve marketing authorization in Europe and the Middle East. With these clinical studies, including PEGINVERA, PROUD-PV, and CONTINUATION-PV, AOP Health opened a new area of treatment options for patients suffering from PV. A further study (PEN-PV) was performed to develop a pen for self-injection allowing ease of self-administration, exact dosing and minimal waste of the medical product. AOP Health’s com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom